Elevated plasma homocysteine is associated with increased brain atrophy rates in older subjects with mild hypertension

Dementia and Geriatric Cognitive Disorders

Volumn 31, Issue 5, 2011, Pages 341-348

  Narayan, Sunil K ^a   Firbank, Michael J ^a   Saxby, Brian K ^c   Stansby, Gerard ^b   Hansrani, Monica ^b   O'Brien, John T ^a   Ford, Gary A ^a,d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Cognitive Drug Research Ltd ^*  (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

B12; Brain atrophy; Folate; Homocysteine; Hypertension; White matter lesions

Indexed keywords

CANDESARTAN HEXETIL; HOMOCYSTEINE;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN INFARCTION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SILENT BRAIN INFARCT; SYSTOLIC BLOOD PRESSURE; WHITE MATTER;

AGED; AGED, 80 AND OVER; ANATOMY, CROSS-SECTIONAL; ATROPHY; BRAIN; CEREBRAL INFARCTION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERTENSION; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; REGRESSION ANALYSIS; RIBOFLAVIN; RISK FACTORS;

EID: 79955977952     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000328118     Document Type: Article

References (24)

1. Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clarke R, Breteler MM: Homocysteine and cognitive function in the elderly: The Rotterdam Scan Study. Neurology 2002; 59: 1375-1380. (Pubitemid 35285990) (Pubitemid 35285990)
2. Koseoglu E, Karaman Y: Relations between homocysteine, folate and vitamin B12 in vascular dementia and in Alzheimer disease. Clin Biochem 2007; 40: 859-863. (Pubitemid 47077412) (Pubitemid 47077412)
3. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimers disease. N Engl J Med 2002; 346: 476-483. (Pubitemid 34441738) (Pubitemid 34441738)
4. Hogervorst R, Ribeiro HM, Molyneux A, Budge M, Smith AD: Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002; 59: 787-793. (Pubitemid 34517761) (Pubitemid 34517761)
5. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM: Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002; 51: 285-289. (Pubitemid 34206283) (Pubitemid 34206283)
6. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM: Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003; 126: 170-175. (Pubitemid 36068567) (Pubitemid 36068567)
7. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002; 58: 1539-1541. (Pubitemid 34552965) (Pubitemid 34552965)
8. Liao D, Cooper L, Cai J, Toole J, Bryan N, Burke G, Shahar E, Nieto J, Mosely T, Heiss G: The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender and cardiovascular disease risk factors: The ARIC study. Neuroepidemiology 1997; 16: 149-162. (Pubitemid 27215864) (Pubitemid 27215864)
9. Gillette-Guyonnet S, Abellan Van Kan G, Andrieu S, Barberger-Gateau P, Berr C, Bonnefoy M, Dartigues JF, De Groot L, Ferry M, Galan P, Hercberg S, Jeandel C, Morris MC, Nourhashemi F, Payette H, Poulain JP, Portet F, Roussel AM, Ritz P, Rolland Y, Vellas B: IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 2007; 11: 132-152. (Pubitemid 46725290) (Pubitemid 46725290)
10. Yang LK, Wong KC, Wu MY, Liao CS, Kuo CS, Huang RF: Correlations between folate, B12, homocysteine levels, and radiological markers of neuropathology in elderly post-stroke patients. J Am Coll Nutr 2007; 26: 272-278.
11. Saxby BK, Harrington F, Wesnes KA, Mc- Keith IG, Ford GA: Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial. Neurology 2008; 70: 1858-1866. (Pubitemid 351653953) (Pubitemid 351653953)
12. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875-886. (Pubitemid 36677151) (Pubitemid 36677151)
13. Fox NC, Freeborough PA: Brain atrophy progression measured from registered serial MRI: Validation and application to Alzheimers disease. J Magn Reson Imaging 1997; 7: 1069-1075. (Pubitemid 28372883) (Pubitemid 28372883)
14. Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O'Brien JT, Ford GA: Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. J Neurol 2007; 254: 713-721. (Pubitemid 47012443) (Pubitemid 47012443)
15. Firbank MJ, Minett T, O'Brien JT: Changes in DWI and MRS associated with white matter hyperintensities in elderly subjects. Neurology 2003; 61: 950-954. (Pubitemid 37248651) (Pubitemid 37248651)
16. Wilson DH, Herrmann R, Hsu S, Biegalski T, Sohn L, Forsythe C, Novotny M, Beggs M, Manderino G: Ion capture assay for folate with the Abbott IMx analyzer. Clin Chem 1995; 41: 1780-1781.
17. Seshadri S, Wolf PA, Beiser A, Selhub J, Au R, Jacques PF, Yoshita M, Rosenberg IH, D'Agostino RB, DeCarli C: Association of plasma total homocysteine levels with subclinical brain injury: Cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008; 65: 642-649. (Pubitemid 351679660) (Pubitemid 351679660)
18. Williams JH, Pereira EA, Budge MM, Bradley KM: Minimal hippocampal width relates to plasma homocysteine in communitydwelling older people. Age Ageing 2002; 31: 440-444. (Pubitemid 35452788) (Pubitemid 35452788)
19. Bertsch T, Mielke O, Holy S, Zimmer W, Casarin W, Aufenanger J, Walter S, Muehlhauser F, Kuehl S, Ragoschke A, Fassbender K: Homocysteine in cerebrovascular disease: An independent risk factor for subcortical vascular encephalopathy. Clin Chem Lab Med 2001; 39: 721-724. (Pubitemid 32894418) (Pubitemid 32894418)
20. Mulder C, van der Flier WM, Veerhuis R, Bouwman F, Jakobs C, Verhoeven NM, Barkhof F, Scheltens P, Blankenstein MA: Association between vitamin B6 and white matter hyperintensities in patients with Alzheimers disease not mediated by homocysteine metabolism. J Am Geriatr Soc 2007; 55: 956-958. (Pubitemid 47011034) (Pubitemid 47011034)
21. Matsui T, Nemoto M, Maruyama M, Yuzuriha T, Yao H, Tanji H, Ootsuki M, Tomita N, Matsushita S, Higuchi S, Yoshida Y, Seki T, Iwasaki K, Furukawa K, Arai H: Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimers disease. Neurodegenerative Diseases 2005; 2: 299-304.
22. Seshadri S, Wolf PA: Homocysteine and the brain: Vascular risk factor or neurotoxin? Lancet Neurology 2003; 2: 11. (Pubitemid 37443337) (Pubitemid 37443337)
23. Firbank MJ, Narayan SK, Saxby BK, Ford GA, O'Brien JT: Homocysteine is associated with hippocampal and white matter atrophy in older subjects with mild hypertension. Int Psychogeriatr 2010; 22: 804-811.
24. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-1455. (Pubitemid 28525506) (Pubitemid 28525506)